![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RL Bell, JB Bouska, PE Malo, C Lanni, RR Harris, ER Otis, AO Stewart, DW Brooks and GW Carter
Immunosciences Research Area, Abbott Laboratories, Abbott Park, Illinois.
As in vitro glucuronidation assay and several biochemical assays were utilized to discover potent new N-hydroxyurea-containing 5-lipoxygenase inhibitors with long durations of action. The best of these, A-78773, is a racemic mixture of two enantiomers. These enantiomers were purified and the R(+)-enantiomer A-79175 was found to be superior to the S(-)-enantiomer with respect to in vitro metabolism and duration of action in the monkey. A-79175 was a potent selective inhibitor of 5- hydroxyeicosatetraenoic acid formation in rat basophilic leukemic homogenates (IC50 = 54 nM) and of calcium ionophore-induced leukotriene B4 (LTB4) formation in purified human polymorphonuclear leukocytes (IC50 = 25 nM) and human whole blood (IC50 = 80 nM). The compound inhibited LT formation in the rat with oral ED50s of 1 to 2 mg/kg. It also was a potent inhibitor of edema and inflammatory cell influx in rats and mice. A-79175 was resistant to glucuronidation and had an elimination half-life of nearly 9 hr in cynomolgus monkeys. A-79175 inhibited ex vivo LTB4 formation by monkeys for extended periods. A single 0.5-mg/kg oral dose gave > 50% inhibition of calcium ionophore- induced LTB4 formation ex vivo for 12 hr. A good correlation was found between the elimination half-life for A-78773 and its enantiomers in cynomolgus monkeys and humans. These data indicate that A-79175 is a promising long-acting agent that should be useful to delineate the importance of LTs in animal and human studies.
This article has been cited by other articles:
|
|
 |
|
  J. Haynes Jr, B. S. Baliga, B. Obiako, S. Ofori-Acquah, and B. Pace Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway Blood, May 15, 2004; 103(10): 3945 - 3950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Kachur, L. J. Askonas, D. Villani-Price, N. Ghoreishi-Haack, S. Won-Kim, C.-D. D. Liang, M. A. Russell, and W. G. Smith Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A4 Hydrolase II: In Vivo Studies J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rioux and A. Castonguay The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-{kappa}B Carcinogenesis, September 1, 2000; 21(9): 1745 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bouska, R. L. Bell, C. L. Goodfellow, A. O. Stewart, C. D. W. Brooks, and G. W. Carter Improving the In Vivo Duration of 5-Lipoxygenase Inhibitors. Application of an In Vitro Glucuronosyltransferase Assay Drug Metab. Dispos., September 1, 1997; 25(9): 1032 - 1038. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Bell, R. R. Harris, P. E. Malo, J. B. Bouska, T. K. Shaughnessy, K. I. Hulkower, C. D. W. Brooks, and G. W. Carter ABT-761 Attenuates Bronchoconstriction and Pulmonary Inflammation in Rodents J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1366 - 1373. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
